Global HER-2 Positive Breast Cancer Market 2015-2019

Global HER-2 Positive Breast Cancer Market 2015-2019

About HER-2 Positive Breast Cancer

Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.

TechNavio's analysts forecast the Global HER-2 Positive Breast Cancer market to grow at a CAGR of 9.90 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global HER-2 Positive Breast Cancer Market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutic agents, chemotherapeutic agents, and hormonal therapies that are used in the management of HER-2 positive breast cancer patients. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global HER-2 Positive Breast Cancer market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, Global HER-2 Positive Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global HER-2 Positive Breast Cancer market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.Key Regions

  • Americas
  • APAC
  • EMEA
Key Vendors
  • Celgene
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Sanofi
Other Prominent Vendors
  • Actavis
  • Array BioPharma
  • Biocad
  • Biocon
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celltrion
  • Chugai Pharmaceutical
  • DARA BioSciences
  • EddingPharm
  • Eisai
  • Galena Biopharma
  • Halozyme Therapeutics
  • Hospira
  • Mylan
  • Oncothyreon
  • Pfizer
  • ProStrakan
  • Puma Biotechnology
  • Sun Pharmaceutical Industries
  • Synta Pharmaceuticals
  • Teva Pharmaceutical
Market Driver
  • Increase in Population of Breast Cancer Patients
  • For a full, detailed list, view our report
Market Challenge
  • Poor Diagnosis and Screening
  • For a full, detailed list, view our report
Market Trend
  • Increase in Awareness
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

TechNavio Announces the Publication of its Research Report – Global HER-2 Positive Breast Cancer Market 2015-2019

TechNavio recognizes the following companies as the key players in the Global HER-2 Positive Breast Cancer Market: Celgene Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG and Sanofi SA.

Other Prominent Vendors in the market are: Actavis, Array BioPharma, Biocad, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Chugai Pharmaceutical, DARA BioSciences, EddingPharm, Eisai, Galena Biopharma, Halozyme Therapeutics, Hospira, Mylan, Oncothyreon, Pfizer, ProStrakan, Puma Biotechnology, Sun Pharmaceutical Industries, Synta Pharmaceuticals and Teva Pharmaceutical.

Commenting on the report, an analyst from TechNavio’s team said: “Increased public awareness is a key trend, which is expected to positively impact the growth of the market. Awareness and screening programs can help diagnose potential cases of breast cancer that would otherwise remain undetected till the late stages.”

According to the report, the increase in the prevalence of breast cancer is a major driver, which is expected to affect the overall market growth in the next five years. With the growing incidence of breast cancer, more and more people are opting for the treatment regimen.

Further, the report states that late-stage diagnosis and expensive screening techniques pose a challenge to the market and have a negative impact on the market growth. Expensive screening techniques like mammography screening lead to poor response from patients.

Companies Mentioned

Celgene, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Sanofi, Actavis, Array BioPharma, Biocad, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb , Celltrion, Chugai Pharmaceutical, DARA BioSciences, EddingPharm , Eisai , GalenaBiopharma, Halozyme Therapeutics, Hospira , Mylan , Oncothyreon, Pfizer , ProStrakan, Puma Biotechnology, Sun Pharmaceutical Industries , Synta Pharmaceuticals, Teva Pharmaceutical

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
    • Table Executive Summary of Global HER-2 Positive Breast Cancer Market 2015-2019
  • Disease Overview
    • Understanding the Disease
    • Pathophysiology
      • Table Pathophysiology: HER-2 Positive Breast Cancer
    • Epidemiology
      • Table Prevalence of HER-2 Positive Breast Cancer in US 2014
    • Diagnosis
      • IHC
        • Table Diagnosis of HER-2 Positive Breast Cancer: IHC
      • FISH
        • Table Diagnosis of HER-2 Positive Breast Cancer: FISH
      • SPoT-Light HER-2 CISH Test
      • Inform HER-2 Dual ISH Test
    • Management
      • Table Management of HER-2 Positive Breast Cancer
      • Surgery
      • Radiotherapy
      • Chemotherapy
      • Targeted Therapy
        • Table ASCO Treatment Guidelines: HER-2 Positive Breast Cancer
      • Hormonal Therapy
    • Economic Burden
      • Table Snapshot of Economic Burden of HER-2 Positive Breast Cancer Market in US
  • Pipeline Analysis
    • Table Pipeline Snapshot: Combination Therapies
    • Table Pipeline Snapshot: Therapeutic Vaccines
  • Market Landscape
    • Market Overview
      • Table Snapshot of Global HER-2 Positive Breast Cancer Market 2014
    • Market Size and Forecast
      • Table Global HER-2 Positive Breast Cancer Market 2014-2019 (US$ million)
      • Table Challenges and Drivers in Global HER-2 Positive Breast Cancer Market
    • HER-2 Positive Breast Cancer Market in US
      • Market Size and Forecast
        • Table HER-2 Positive Breast Cancer Market in US 2014-2019 (US$ million)
    • HER-2 Positive Breast Cancer Market in EU
      • Market Size and Forecast
        • Table HER-2 Positive Breast Cancer Market in EU 2014-2019 (US$ million)
    • Five Forces Analysis
  • Market Segmentation by Type of Therapy
    • Global HER-2 Positive Breast Cancer Market by Type of Therapy 2014-2019
      • Table Global HER-2 Positive Breast Cancer Market by Type of Therapy
    • Chemotherapy
      • Alkylating Agents
      • Antimetabolites
      • Cytotoxic Antibiotics
      • Taxanes
    • Targeted Therapy
    • Hormone Therapy
      • Table Global HER-2 Positive Breast Cancer Market by Type of Therapy 2014
  • Market Segmentation by Molecule Type
    • Global HER-2 Positive Breast Cancer Market by Molecule Type 2014-2019
      • Table Global HER-2 Positive Breast Cancer Market by Molecule Type
    • Biologics
    • Small Molecules
      • Table Global HER-2 Positive Breast Cancer Market by Molecule Type 2014
  • Market Segmentation by Route of Administration
    • Global HER-2 Positive Breast Cancer Market by Route of Administration 2014-2019
      • Table Global HER-2 Positive Breast Cancer Market by Route of Administration
    • Oral
    • Parenteral
      • Table Global HER-2 Positive Breast Cancer Market by Route of Administration 2014
  • Geographical Segmentation
    • Global HER-2 Positive Breast Cancer Market by Geographical Segmentation 2014-2019
      • Table Global HER-2 Positive Breast Cancer Market by Geographical Segmentation 2014
  • Buying Criteria
  • Market Growth Drivers
    • Table Growth Drivers of Global HER-2 Positive Breast Cancer Market
  • Drivers and their Impact
  • Market Challenges
    • Table Challenges in Global HER-2 Positive Breast Cancer Market
    • Table Five-year Survival Rate by Stage of Diagnosis (SEER Analysis for 2004-2010)
  • Impact of Drivers and Challenges
  • Market Trends
    • Table Trends in Global HER-2 Positive Breast Cancer Market
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Vendor Ranking 2014
      • Competitive Assessment of Top Drugs
        • Table Revenue Comparison of Top Drugs for HER-2 Positive Breast Cancer 2013 (US$ million)
      • Celgene
        • Table Product Portfolio: Celgene
        • Table YoY Growth Rate and Revenue of Abraxane 2010-2013 (US$ million)
      • F. Hoffmann-La Roche
        • Table Product Portfolio: F. Hoffmann-La Roche
        • Table YoY Growth Rate and Revenue of Herceptin 2010-2013 (US$ million)
        • Table Revenue of Perjeta 2012 and 2013 (US$ million)
        • Table Yoy Growth Rate and Revenue of Xeloda 2010-2013 (US$ million)
      • GlaxoSmithKline
        • Table Product Portfolio: GlaxoSmithKline
        • Table Yoy Growth Rate and Revenue of Tykerb 2010-2013 (US$ million)
      • Novartis
        • Table Product Portfolio: Novartis
        • Table Yoy Growth Rate and Revenue of Femara 2010-2013 (US$ million)
      • Sanofi
        • Table Product Portfolio: Sanofi
        • Table Yoy Growth Rate and Global Revenue of Taxotere 2010-2013 (US$ million)
    • SWOT Analysis of Targeted Therapies
      • Herceptin
        • Table Herceptin: SWOT Analysis
      • Kadcyla
        • Table Kadcyla: SWOT Analysis
      • Perjeta
        • Table Perjeta: SWOT Analysis
      • Tykerb
        • Table Tykerb: SWOT Analysis
    • Other Prominent Vendors
  • Key Vendor Analysis
    • Celgene
      • Key Facts
      • Business Overview
      • Business Strategy
      • Business Segmentation by Revenue
        • Table Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
      • Sales by Geography
        • Table Celgene: Sales by Geography 2013
      • Key Information
      • SWOT Analysis
    • F. Hoffmann-La Roche
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
      • Sales by Geography
        • Table F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
        • Table F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • GlaxoSmithKline
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table GlaxoSmithKline: Business Segmentation 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
      • Sales by Geography
        • Table GlaxoSmithKline: Sales by Geography 2013
      • Pipeline Products
        • Table GlaxoSmithKline: Pipeline Products 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Novartis
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Novartis AG: Business Segmentation
      • Revenue by Business Segmentation
        • Table Novartis AG: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
      • Sales by Geography
        • Table Novartis AG: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Sanofi
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Sanofi SA: Business Segmentation
      • Revenue by Business Segmentation
        • Table Sanofi SA: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
      • Sales by Geography
        • Table Sanofi SA: Sales Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook